Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Danish Cancer Society Research Center to advance clinical development of its drug candidates, LP-100 and LP-184. This partnership aims to enhance diagnostic methods for identifying NER-deficient tumors. The collaboration will leverage Lantern's RADR® AI platform, potentially adding millions of data points and expediting cancer treatment discovery. Both LP-100 and LP-184 have shown promise in targeting NER deficiencies, with LP-100 currently in a phase 2 trial for metastatic prostate cancer, showing improved overall survival rates.

Lantern Pharma (LTRN) has expanded its collaboration with the National Cancer Institute (NCI) to enhance the development of its oncology drug candidates, LP-184 and LP-284. This partnership aims to leverage multiomic data to identify gene signatures predicting tumor responses. LP-184 is targeting pancreatic cancer and glioblastoma, while LP-284 focuses on leukemias and lymphomas. Initial results suggest LP-184 may be more effective in tumors resistant to current treatments. The partnership will continue to refine predictive biomarkers and advance clinical trials, with results expected to be published in peer-reviewed journals.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO Panna Sharma will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be a fireside chat with analyst Michael King and will be available on-demand for attendees starting January 10 at 7:00 AM ET. Lantern Pharma utilizes its RADR® A.I. platform for oncology drug development, focusing on biomarker identification to enhance treatment outcomes for patients. More information can be found on their website.

On December 14, 2021, Lantern Pharma (NASDAQ: LTRN) announced positive data on LP-284's efficacy against hematologic cancers presented at the ASH Annual Meeting. LP-284, a synthetic acylfulvene compound, showcased broad anti-tumor activity against lymphoma, multiple myeloma, and leukemia in vitro. The findings suggest LP-284 could serve as a targeted therapy option for cancers with DNA repair deficiencies. Lantern plans to leverage its RADR® A.I. platform to advance LP-284 development and address the urgent need for new treatment options in blood cancers.

Lantern Pharma Inc. (NASDAQ: LTRN) has announced a share repurchase program to buy back up to $7 million of its common stock. This initiative aligns with the company's goal to enhance shareholder value and reflects confidence in its clinical pipeline and RADR^® A.I. platform. As of September 30, 2021, Lantern held approximately $73.8 million in cash and marketable securities, with around 11.2 million shares outstanding as of October 29, 2021. The stock buyback will be executed based on market conditions and regulatory limitations.

Lantern Pharma (NASDAQ: LTRN) announced a virtual Key Opinion Leader (KOL) event on pancreatic cancer treatment featuring drug candidate LP-184. Scheduled for November 18, 2021, at 12:00 pm EST, the event will discuss LP-184's advances, a PTGR1-activated small molecule targeting genetically defined pancreatic cancer patients. Notable co-hosts include Dr. Igor Astsaturov, Dr. Ira Sharp, and Dr. Kishor G. Bhatia. Lantern's RADR® A.I. platform aims to transform oncology drug development. LP-184 has Orphan Drug Designation from the FDA for pancreatic cancer and glioblastoma.

Lantern Pharma (LTRN) announced its abstract on the efficacy of LP-184 in treating glioblastoma multiforme (GBM) has been accepted for virtual presentation at the Society for Neuro-Oncology 2021 Annual Meeting from November 18-21, 2021. The research indicates LP-184's effectiveness in both MGMT methylated and unmethylated GBM, particularly for those with DNA repair deficiencies. LP-184 has also received Orphan Drug Designation for malignant gliomas and pancreatic cancer. The findings support further development as a promising treatment for GBM.

On November 9, 2021, Lantern Pharma (NASDAQ: LTRN) announced its participation in two investor conferences. CEO Panna Sharma will present at the Q4 Investor Summit on November 16 at 11:00 am ET, available via webcast. CFO David Margrave will hold one-on-one meetings at the Torrey Hills Capital 6th Annual Emerging Growth Conference on November 17 in Rancho Santa Fe, California. Lantern Pharma focuses on oncology drug development using its RADR® A.I. platform, which identifies patients likely to respond to targeted therapeutics.

Lantern Pharma (LTRN) announced that its abstract on LP-284 has been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. This study focuses on LP-284's effectiveness in treating hematologic cancers. The drug shows promise as a synthetic analogue of LP-184, specifically targeting blood cancers. The poster presentation will occur on December 13, 2021, with Dr. Jianli Zhou as the presenter. Lantern aims to leverage its RADR® platform to optimize patient responses to its therapies.